OR WAIT null SECS
April 15, 2024
C3TI will promote CDER’s clinical trial innovation activities both internally and externally.
April 02, 2024
There are considerations companies may want to consider before seeking out a service provider.
February 16, 2024
The need for preclinical testing expertise is growing as molecular complexity increases.
October 05, 2023
POINT is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
September 25, 2023
The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
September 02, 2023
There are many promising trials in the pipeline that may bring big news for major therapeutic areas.
August 21, 2023
The expanded operations will also support the start of proline/alanine/serine (PAS)-nomacopan clinical trials in geographic atrophy (GA).
August 10, 2023
The initial collaboration between the two companies began in 2017 with an extension announced in 2021.
July 27, 2023
The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.
June 08, 2023
The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.